Apogee Therapeutics, Inc. Financing Cash Flow
Apogee Therapeutics, Inc. (APGE) reported Financing Cash Flow of $518.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $107.02M, a 8969.24% increase year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $411.17M, a 66004.02% increase year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $374.95M, a 745.32% increase year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $19.74M, a 5053.52% increase year-over-year.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $396.49M, a 19.92% decline from fiscal 2024.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $495.11M, a 56.98% increase from fiscal 2023.
- Apogee Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $315.39M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 8 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 11 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $107.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $518.18M 10-Q · filed 2026-08-10 | $893.13M derived: sum of 3 quarters · filed 2026-08-10 | $912.87M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $411.17M 10-Q · filed 2026-05-11 | $786.12M derived: sum of 2 quarters · filed 2026-05-11 | $805.86M derived: sum of 3 quarters · filed 2026-05-11 | $807.03M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $374.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $394.69M derived: sum of 2 quarters · filed 2026-03-02 | $395.87M derived: sum of 3 quarters · filed 2026-08-10 | $396.49M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $19.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $20.92M derived: sum of 2 quarters · filed 2026-08-10 | $21.54M 10-Q · filed 2025-11-10 | $65.90M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.80M 10-Q · filed 2026-08-10 | $46.16M derived: sum of 3 quarters · filed 2026-08-10 | $46.54M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $622.00K 10-Q · filed 2026-05-11 | $44.98M derived: sum of 2 quarters · filed 2026-05-11 | $45.36M derived: sum of 3 quarters · filed 2026-05-11 | $45.21M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $44.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $44.74M derived: sum of 2 quarters · filed 2026-03-02 | $44.59M derived: sum of 3 quarters · filed 2026-03-02 | $495.11M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $233.00K derived: sum of 2 quarters · filed 2025-11-10 | $450.75M 10-Q · filed 2025-11-10 | $450.54M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | -$150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $450.37M 10-Q · filed 2025-08-11 | $450.16M derived: sum of 3 quarters · filed 2026-03-02 | $767.46M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $450.52M 10-Q · filed 2025-05-12 | $450.31M derived: sum of 2 quarters · filed 2026-03-02 | $767.61M derived: sum of 3 quarters · filed 2026-03-02 | ||||
| 2023-12-31 | -$213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $317.08M derived: sum of 2 quarters · filed 2026-03-02 | $315.39M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $317.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $315.60M 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | -$1.69M 10-Q · filed 2024-08-12 | ||||||
| 2022-12-31 | $168.32M 10-K · filed 2024-03-05 | ||||||
| 2022-09-30 | $9.82M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | $4.97M 10-Q · filed 2023-08-28 |